Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 31;14(1):47.
doi: 10.1186/s40545-021-00328-5.

Pharmacoeconomics in Africa: needs, prospect and challenges

Temitope Ben-Ajepe  1 , Ifechukwu Benedict Nwogu  2 , Damilola Quazeem Olaoye  3 , Abdulhafeez Ayodele Mustapha  4 , Theogene Uwizeyimana  5 , Yusuff Adebayo Adebisi  3   6
Affiliations

Pharmacoeconomics in Africa: needs, prospect and challenges

Temitope Ben-Ajepe et al. J Pharm Policy Pract. .

Abstract

Africa as a continent has experienced a continuous increase in the cost of healthcare as its demands increase. With many of these African countries living below the poverty threshold, Africans continue to die from preventable and curable diseases. Population increases have led to an increase in demands for healthcare, which unfortunately have been met with inequitable distribution of drugs. Hence, the outcomes from healthcare interventions are frequently not maximized. These problems notably call for some economic principles and policies to guide medication selection, procurement, or donation for population prioritization or health insurance. Pharmacoeconomics drives efficient use of scarce or limited resources to maximize healthcare benefits and reduce costs. It also brings to play tools that rate therapy choice based on the quality of life added to the patient after a choice of intervention was made over an alternative. In this paper, we commented on the needs, prospect, and challenges of pharmacoeconomics in Africa.

Keywords: Africa; Challenges; Needs; Pharmacoeconomics; Prospect.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interest.

Similar articles

See all similar articles

Cited by

References

    1. Thwaites R, Townsend RJ. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective. Pharmacoeconomics. 1998;13:175–180. doi: 10.2165/00019053-199813020-00002. - DOI - PubMed
    1. WHO. Equitable access to essential medicines : a framework for collective action. World Health Organization; 2004. https://apps.who.int/iris/handle/10665/68571. Accessed 20 Mar 2021.
    1. Akande-Sholabi W, Adebisi YA. The impact of COVID-19 pandemic on medicine security in Africa: Nigeria as a case study. Pan Afr Med J. 2020;35(Suppl 2):73. doi: 10.11604/pamj.supp.2020.35.2.23671. - DOI - PMC - PubMed
    1. Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004;329:1169–1172. doi: 10.1136/bmj.329.7475.1169. - DOI - PMC - PubMed
    1. Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr Ther Res. 2008;69:268–285. doi: 10.1016/j.curtheres.2008.06.005. - DOI - PMC - PubMed